Lixte Biotechnology (NASDAQ:LIXT) Releases Quarterly Earnings Results

Lixte Biotechnology (NASDAQ:LIXT) issued its quarterly earnings results on Monday. The company reported ($0.27) earnings per share for the quarter, Zacks reports.

Lixte Biotechnology Price Performance

Lixte Biotechnology stock opened at $1.30 on Tuesday. The company has a market cap of $2.93 million, a price-to-earnings ratio of -0.75 and a beta of 0.19. The firm has a 50-day moving average of $1.79 and a 200-day moving average of $1.88. Lixte Biotechnology has a one year low of $1.02 and a one year high of $4.40.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.